Modulation of IRF7-driven transcription as a strategy to control HIV-1 latency

TL;DR

This paper explores using IRF7 modulation to control HIV-1 latency, offering a new strategy to suppress the virus without immune activation.

Contribution

The study introduces pacritinib as a novel latency-promoting agent that targets IRF7 to suppress HIV-1 transcription.

Findings

Pacritinib suppresses HIV-1 latency reversal without immune activation.

IRF7 downregulation by pacritinib correlates with reduced HIV-1 transcription.

Pacritinib inhibits multiply spliced HIV-1 transcripts, blocking late transcriptional stages.

Abstract

The persistence of latent HIV-1 reservoirs remains a major barrier to achieving a cure for HIV. While latency-reversing agents (LRAs) have been extensively studied, latency-promoting agents (LPAs) offer a complementary strategy to silence viral transcription and prevent immune activation. Here, we propose that modulation of IRF7-driven transcription may represent a novel approach to control HIV-1 latency, by characterizing the role of the Janus kinase 2 inhibitor (JAK2i) pacritinib as a novel latency-promoting agent (LPA).

The impact of JAK2i on HIV-1 reactivation, immune activation, and IRF7 expression were evaluated in lymphoid and myeloid HIV-1 latency models, as well as ex vivo CD4+ T cells from ART-suppressed individuals. IRF7 modulation was assessed by qRT-PCR and immunoblotting, and its functional role confirmed through LTR transactivation assays and IRF7 overexpression. Co-immunoprecipitation was used to detect IRF7–Tat interaction. Whole transcriptomic profiling with pathway analysis were performed to identify the molecular signatures associated with JAK2i treatment.

Pacritinib effectively suppressed HIV-1 latency reversal induced by LRAs without triggering immune activation. Mechanistically, pacritinib downregulated IRF7 expression at both transcript and protein levels, correlating with reduced HIV-1 transcription. Overexpression of IRF7 restored LTR transactivation, confirming its central role in HIV-1 transcription and latency. Co-immunoprecipitation assays revealed a direct interaction between IRF7 and the viral transactivator Tat. Furthermore, pacritinib selectively inhibited multiply spliced HIV-1 transcripts, suggesting a blockade at late transcriptional stages.

Pacritinib acts as a potent LPA by silencing HIV-1 transcription through IRF7 downregulation, supporting a promising “block and lock” strategy for functional cure approaches. Targeting IRF7 may enable durable suppression of the viral reservoir without immune activation, supporting the development of “block and lock” therapies.

Figures